Publication | Open Access

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

InflammationRheumatologyBiological TreatmentAnti-inflammatoryRheumatoid DisorderAutoimmune DiseaseRheumatic DiseasesImmunologyClinical TrialsOsteoarthritisInflammatory Rheumatic DiseaseImmunotherapyMedicineRheumatoid Arthritis